Grid Therapeutics is planning to start trials of its lead cancer immunotherapy next year after raising $5 million in second-round financing. The antibody drug, called GT103, is thought to work by ...
In the last decade, there has been a paradigm shift in cancer treatment. Dr. Andrew L. Pecora, chief innovations officer, professor and vice president of cancer services at John Theurer Cancer Center ...
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present ...
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
UCLA is the latest institution to join Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. Through the I-O RPM program, BMS and the David Geffen ...
Deerfield Management is leading a $75 million round for a new biotech startup dubbed Akari Therapeutics, which was created out of Celsus Therapeutics' recent acquisition of Volution Immuno ...
Moleculent’s Techstart program gives researchers early access to its high-plex platform for mapping direct cell-cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback